| Phase 18 trials |
|
Phase 1
|
NCT06886269 |
Mar → May 2025 |
— |
Vertex Pharmaceuticals Incorporated |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06523595 |
Jul → Dec 2024 |
— |
Vertex Pharmaceuticals Incorporated |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06508762 |
Jul → Sep 2024 |
— |
Vertex Pharmaceuticals Incorporated |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06420765 |
May 2024 → Mar 2025 |
— |
Vertex Pharmaceuticals Incorporated |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06394167 |
May 2024 → Feb 2025 |
— |
Vertex Pharmaceuticals Incorporated |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06392659 |
May → Jul 2024 |
— |
Vertex Pharmaceuticals Incorporated |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06226454 |
Jan → Jun 2024 |
— |
Vertex Pharmaceuticals Incorporated |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05653323 |
Dec 2022 → Sep 2023 |
— |
Vertex Pharmaceuticals Incorporated |
Completed
|
No outcome recorded
|
| Phase 22 trials |
|
Phase 2
|
NCT06619847 |
Oct 2024 → May 2025 |
— |
Vertex Pharmaceuticals Incorporated |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT06619860 |
Oct 2024 → Mar 2027 expected |
diabetic neuropathy |
Vertex Pharmaceuticals Incorporated |
Recruiting
|
No outcome recorded
|